Back to search results

Suzetrigine for Pain After Cardiac or Bariatric Surgery

This study is testing a new pain medication called Suzetrigine for people having heart surgery (with a sternotomy, which is a cut through the breastbone) or weight-loss surgery (bariatric surgery). Suzetrigine works by blocking specific pain signals from reaching your brain and spinal cord. Researchers want to see if adding Suzetrigine to standard pain care can reduce the amount of opioid pain medication you need and improve your pain scores after surgery. You may be eligible if you are between 18 and 85 years old and scheduled for one of these surgeries. The study is comparing Suzetrigine to a placebo (an inactive substance). The main goal is to measure how much opioid medication you use over 5 days after surgery. The current recruitment status is unclear.

Study design
This is a randomized study, meaning you would be randomly assigned to receive either Suzetrigine or a placebo. It plans to enroll 235 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your opioid consumption will be measured for 5 days after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07539623

Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

Recruiting
PHASE3Ages 18–85InterventionalTreatment
Icahn School of Medicine at Mount Sinai
~235 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:SuzetriginePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Opioid Consumption
Measured over 5 days

Conditions

Bariatric Surgery
Cardiac Surgery With Sternotomy
Post-operative Pain

Explore related trials

Bariatric SurgeryCardiac SurgeryPost-Operative Pain

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Himani Bhatt, DO · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Himani Bhatt, DO
[email protected]
212-523-2500
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults 18-85 years old
Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)
All genders

Exclusion

ASA Class V
Urgent or emergent surgery
Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)
History of substance use disorder or chronic opioid use
Reoperation
Patient refusal or inability to consent
Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and
Clarithromycin)
Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)

What this trial measures

  • Opioid Consumption5 days

    Total post-operative opioid consumption measured daily in total morphine milligram equivalents.